However, while the variations in these factors for amino acids, acylcarnitines, and other traditional screening biomarkers have been thoroughly investigated, relatively few studies have specifically focused on the newly incorporated ADO marker, which is part of the NeoBase2 kit used for detecting metabolic disorders. The gene discussed is ADO; the disease is Other metabolic disease.